Yu EY, Petrylak DP, O'Donnell PH, et al. - In this study, the efficacy and safety of enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients were explored. Researchers enrolled a total of 91 patients at 40 sites globally, of whom 89 received treatment between Oct 8, 2017, and Feb 11, 2020. This study’s findings demonstrate that the treatment with enfortumab vedotin was tolerable and confirmed responses were seen in 52% of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma who were previously treated with PD-1 or PD-L1 inhibitors. According to the results, these individuals have few treatment options, and enfortumab vedotin could be a promising new therapy for a patient population with a high unmet need.